Marcel Rozencweig becomes President of Innate Pharma Inc., based in the US
MARSEILLE, France, Sept. 16, 2014 (GLOBE NEWSWIRE) -- Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today announces the nomination of Pierre Dodion as Chief Medical Officer (CMO) and member of the Executive committee.
Pierre Dodion is a medical oncologist, with a specialization degree in Oncology from the Free University of Brussels, Belgium and a MBA degree from the Saint Joseph University of Philadelphia, PA. Pierre Dodion is a senior executive with 25 years of experience in the pharmaceutical industry having worked at Pfizer, Novartis and Aventis. He contributed to the development, approval and launch of several drugs, including sunitinib (Sutent®, kidney cancer and GIST) and letrozole (Femara®, breast cancer).
In 2007, Pierre Dodion joined ARIAD Pharmaceuticals (Nasdaq: ARIA), first as SVP and Chief Medical Officer, then as SVP Corporate Development and Operations. He played a major role in the expansion of ARIAD, notably in Europe. He contributed to two development programs in oncology: ridaforolimus (licensed to Merck) and ponatinib (marketed by ARIAD Pharmaceuticals as Iclusig®).
Pierre Dodion is appointed CMO of Innate Pharma, replacing Marcel Rozencweig who becomes President of Innate Pharma Inc., Innate's fully-owned US subsidiary. Marcel Rozencweig will represent the Company in its interaction with US stakeholders and remains a member of the Executive Committee of Innate Pharma SA.
Hervé Brailly, Chief Executive Officer and co-founder of Innate Pharma, commented: « As we have embarked on a new ambitious phase of development, with the launch of five clinical trials with the anti-NKG2A antibody, we are indeed very pleased to benefit from Pierre Dodion's expertise and experience. We can rely on his deep understanding of clinical and regulatory activities to help us move to the next steps of our development. » He added: « Since 2009, Marcel Rozencweig's contribution has been decisive to the design of our clinical development strategy and the implementation of our partnership with Bristol-Myers Squibb. Marcel will continue to play a major role in growing our business in the US. »
Pierre Dodion commented: « Immunotherapy has established itself as a genuine paradigm shift in cancer therapy. Innate Pharma holds a unique position in this new field, with soon three clinical-stage drug candidates. I am delighted to be part of this therapeutic revolution by joining a pioneer team, one of the first ones in Europe to bet on immuno-oncology. »
Marcel Rozencweig commented: « Over the past 3 years, Innate Pharma truly changed its dimension and I am proud and happy to have been part of it. The future of Innate Pharma now is closely linked with its expansion and activities in the US, where a major part of immunotherapy development is taking place, and I am very pleased to continue to contribute as President of Innate Pharma Inc."
About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical company discovering and developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory diseases.
Its innovative approach has translated into major alliances with leaders in the biopharmaceutical industry such as Bristol-Myers Squibb and Novo Nordisk A/S.
The Company has two clinical-stage programs in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body's own immune cells to recognize and kill cancer cells. Innate Pharma science also has potential in chronic inflammatory diseases.
Listed on Euronext-Paris, Innate Pharma is based in Marseille, France, and had 90 employees as at June 30, 2014.
Learn more about Innate Pharma at www.innate-pharma.com.
Practical Information about Innate Pharma shares:
ISIN code FR0010331421
Ticker code IPH
This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma's website.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
For additional information, please contact:
Innate Pharma ATCG Press
Director, Investor Relations - Tel.: +33 (0)4 30 30 30 87
Judith Aziza, Mob.:+33 (0)6 70 07 77 51
Marielle Bricman, Mob.:+33 (0)6 26 94 18 53